Cue Biopharma Current Ratio 2016-2021 | CUE

Cue Biopharma current ratio from 2016 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Cue Biopharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.08B $0.02B 4.78
2021-03-31 $0.08B $0.02B 4.65
2020-12-31 $0.09B $0.02B 5.37
2020-09-30 $0.09B $0.01B 6.58
2020-06-30 $0.09B $0.02B 5.95
2020-03-31 $0.05B $0.01B 4.23
2019-12-31 $0.06B $0.01B 5.24
2019-09-30 $0.03B $0.01B 3.18
2019-06-30 $0.03B $0.01B 2.65
2019-03-31 $0.03B $0.01B 3.02
2018-12-31 $0.04B $0.01B 6.53
2018-09-30 $0.04B $0.01B 8.86
2018-06-30 $0.05B $0.00B 16.62
2018-03-31 $0.06B $0.00B 13.70
2017-12-31 $0.07B $0.01B 12.17
2017-09-30 $0.00B 0.00
2017-06-30 $0.00B 0.00
2017-03-31 $0.00B 0.00
2016-12-31 $0.02B $0.00B 14.27
2015-12-31 $0.01B $0.00B 19.12
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.375B $0.003B
Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76